drugset / Trial / NCT05292625
Stem Cell Infusion in the Treatment of Patients with Neurological Sequelae After Ischemic Stroke
RandomizedParallel-groupSingle-blindTreatment
Summary
This trial is to investigate the safety and potential therapeutic efficacy of allogeneic administration of umbilical cord-derived MSCs (UC-MSCs) in combination with standard neurological complications after ischemic stroke treatment in Vietnam.
Timeline
- Start
- 2020-07-07
- Primary completion
- 2022-12-30
- Completion
- 2023-11-30
Publications
- Nguyen LT, Nguyen TTN, Nguyen KT, Phung LN, Hoang VT, Phan TTK, Van Pham M, Nguyen ATP, Van Ngo D, Van Nguyen A, Van Nguyen C. Intrathecal versus intravenous umbilical cord mesenchymal stem cells for ischemic stroke sequelae. Stem Cells Transl Med. 2025 Nov 24;14(12):szaf063. doi: 10.1093/stcltm/szaf063.
- Hoang VT, Le DS, Hoang DM, Phan TTK, Ngo LAT, Nguyen TK, Bui VA, Nguyen Thanh L. Impact of tissue factor expression and administration routes on thrombosis development induced by mesenchymal stem/stromal cell infusions: re-evaluating the dogma. Stem Cell Res Ther. 2024 Feb 27;15(1):56. doi: 10.1186/s13287-023-03582-3.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | human umbilical cord mesenchymal stem cells | Cell therapy | 1.5 cells/kg | Intravenous |
| Subject | human umbilical cord mesenchymal stem cells | Cell therapy | 1.5 cells/kg | Intrathecal |